Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexFemale
Age45-70
SponsorUniversity of Connecticut
About this trial
The goal of this clinical trial is to evaluate the effects of blackcurrant (BC) supplementation on changes in bone density and gut microbiome composition in postmenopausal females.
Eligibility criteria
Qualifiers
postmenopausal (defined as no more than 10 years since final menstrual cycle) females aged 45-70 years
not on hormone replacement therapy for at least one year before initiation of the study
maintaining normal exercise level (< 7 hours/week) and willing to avoid exercise for 24 hours prior to blood and stool sampling
willing to ingest a dietary blackcurrant supplement or placebo (up to 1,176 mg/day, three 392mg capsules)
Disqualifiers
history of cardiovascular disease, osteoporosis, metabolic bone disease, cancer, diabetes mellitus, arthritis, or other chronic inflammatory diseases
current smokers
taking prescription medications known to alter bone and calcium metabolism
taking anabolic agents such as parathyroid hormone or growth hormone, or steroid within 3 months before the start of the study
Trial design
Treatments tested in this trial
- Blackcurrant (BC) extract
- Blackcurrant (BC) extract
- Placebo
Treatment groups
159 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov